氨溴索联合特布他林、布地奈德应用于小儿支气管肺炎的效果

Effect of Ambroxol Combined with Terbutaline and Budesonide in the Treatment of Children with Bronchopneumonia

目的:探讨氨溴索联合特布他林、布地奈德应用于小儿支气管肺炎的效果。方法:选取2020年1月—2022年12月当阳市人民医院收治的80例小儿支气管肺炎患者,采用随机数表法将其分成A组与B组,各40例。A组采用特布他林+布地奈德进行治疗,B组在A组基础上加用氨溴索治疗。观察和比较两组症状、体征改善时间、不良反应发生情况、炎症因子指标、肺功能指标。结果:B组气喘缓解时间、止咳时间、胸片阴影消失时间与啰音消失时间均早于A组,差异有统计学意义(P<0.05)。治疗前,两组C反应蛋白(CRP)、肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)比较,差异无统计学意义(P>0.05);治疗后,两组CRP、TNF-α、IL-6低于治疗前,且B组均低于A组,差异有统计学意义(P<0.05)。治疗前,两组第1秒用力呼气容积(FEV_1)、用力肺活量(FVC)、呼气流量峰值(PEF)比较,差异无统计学意义(P>0.05);治疗后,两组FEV_1、FVC、PEF均高于治疗前,且B组高于A组,差异有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:氨溴索联合特布他林、布地奈德治疗小儿支气管肺炎可加快其症状、体征的消退速度,显著改善其肺功能,还能有效降低其炎症水平,安全性高。

Objective:To investigate the effect of Ambroxol combined with Terbutaline and Budesonide in children with bronchopneumonia.Method:A total of 80 children with bronchopneumonia treated in the People's Hospital of Dangyang City from January 2020 to December 2022 were selected and divided into group A and group B by random number table method,with 40 cases in each group.Group A was treated with Terbutaline+Budesonide,and group B was treated with Ambroxol on the basis of group A.The improvement time of symptoms and signs,the occurrence of adverse reactions,inflammatory factors indexes and lung function indexes were observed and compared between the two groups.Result:Asthma relief time,cough relief time,shadow disappearance time and rales disappearance time of chest film in group B were earlier than those in group A,and the differences were statistically significant(P<0.05).Before treatment,there were no significant differences in C-reactive protein(CRP),serum tumor necrosis factor-α(TNF-α),interleukin-6(IL-6)between the two groups(P>0.05).After treatment,CRP,TNF-αand IL-6 in two groups were lower than those before treatment,and group B were lower than those in the group A,the differences were statistically significant(P<0.05).Before treatment,there were no significant differences in forced expiratory volume in one second(FEV1),forced vital capacity(FVC),peak expiratory flow(PEF)between the two groups(P>0.05).After treatment,FEV1,FVC and PEF in both groups were higher than those before treatment,and group B were higher than those in group A,the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:The combination of Ambroxol combined with Terbutaline and Budesonide in the treatment of bronchopneumonia in children can accelerate the regression of symptoms and signs,significantly improve lung function,and can also effectively reduce inflammation levels,with high safety.